Silicon Valley tech startups pulled in a total of more than $346 million in venture funding in July. From biotech innovators to data specialists, learn which local standouts secured last month’s largest rounds of capital, and how they plan to invest their newly earned millions.
Largest San Francisco Tech Funding Rounds, July 2023
- Septerna
- Hammerspace
- Ossium Health
- Collective
- Hightouch
#5. $38 million, July 19
Data activation company Hightouch raised a $38 million funding round to launch and grow its Customer 360 platform. The company lets marketing and data teams activate customer data directly from their data warehouse to destinations, such as ad platforms and CRMs. This latest round of funding from lead investor Bain Capital Ventures will go toward developing its Customer 360 Toolkit.
#4. $50 million, July 11
Backed by a new round of capital from investors including Gradient Ventures, Google’s AI fund and Innovius Capital, Collective wants to accelerate AI deployment across its operations and onboard waitlisted enterprise customers. The company developed an online back office platform that manages tasks like business incorporation, accounting, bookkeeping and tax services.
#3. $52 million, July 25
The bioengineering company’s bone marrow banking platform develops stem cell therapies for patients with blood and immune diseases. Ossium Health raised $52 million in Series C funding to grow its bone marrow bank, build on clinical trials and accelerate product development. CPMG led the round.
#2. $56.7 million, July 18
Hammerspace, a San Mateo-based data orchestration company, pulled in $56.7 million in funding led by Prosperity7. Its platform helps companies manage and use large quantities of unstructured data. This latest round of capital will help Hammerspace expand its team from 75 to more than 100 people by the end of the year.
#1. $150 million, July 11
Based in South San Francisco, biotech company Septerna is working to develop oral small molecule medicines targeting G protein-coupled receptors, or GPCRs. Septerna aims to treat hypoparathyroidism, a condition characterized by the hormone that controls blood calcium and phosphate levels. Its Series B round led by RA Capital Management will help Septerna continue product development.
